Your browser is no longer supported. Please, upgrade your browser.
NVUS Novus Therapeutics, Inc. weekly Stock Chart
Novus Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.94 Insider Own2.20% Shs Outstand6.88M Perf Week-2.22%
Market Cap33.37M Forward P/E- EPS next Y-1.47 Insider Trans0.00% Shs Float4.83M Perf Month-13.05%
Income-14.70M PEG- EPS next Q-0.29 Inst Own53.50% Short Float0.35% Perf Quarter27.81%
Sales- P/S- EPS this Y81.40% Inst Trans40.77% Short Ratio0.27 Perf Half Y9.98%
Book/sh2.71 P/B1.79 EPS next Y-5.00% ROA-54.30% Target Price7.50 Perf Year-15.80%
Cash/sh- P/C- EPS next 5Y- ROE-60.40% 52W Range3.12 - 6.60 Perf YTD19.46%
Dividend- P/FCF- EPS past 5Y6.80% ROI- 52W High-26.52% Beta0.14
Dividend %- Quick Ratio13.20 Sales past 5Y- Gross Margin- 52W Low55.45% ATR0.46
Employees8 Current Ratio13.20 Sales Q/Q- Oper. Margin- RSI (14)49.29 Volatility4.71% 8.57%
OptionableNo Debt/Eq0.00 EPS Q/Q80.20% Profit Margin- Rel Volume0.38 Prev Close4.68
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume62.73K Price4.85
Recom2.00 SMA20-3.43% SMA508.54% SMA20011.70% Volume23,749 Change3.63%
Feb-13-18Initiated Ascendiant Capital Markets Buy $7
Apr-02-18 09:00AM  Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update Business Wire -5.95%
Jan-05-18 07:20PM  Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)? Simply Wall St.
Nov-21-17 03:00PM  Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference PR Newswire
12:49PM  Who Are The Largest Shareholders In Novus Therapeutics Inc (NVUS)? Simply Wall St.
Nov-08-17 04:52PM  Novus Therapeutics Reports Third Quarter 2017 Results PR Newswire
Nov-06-17 04:01PM  Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President PR Newswire -6.56%
Oct-05-17 09:26AM  Whats The Outlook For Loss-Making Novus Therapeutics Inc (NVUS)? Simply Wall St.
Aug-09-17 06:08PM  Novus Therapeutics Reports Second Quarter 2017 Results PR Newswire
Jul-10-17 06:30AM  Novus Therapeutics Announces Change in Management PR Newswire
Jun-12-17 08:00AM  Novus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Novus Therapeutics, Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of ear, nose, and throat products. Its lead product is a nasally-administered combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD) conditions. The company also has a foam-based drug delivery technology platform (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. It is developing a foam-based combination drug-product to the external ear canal that is an improved treatment option for acute otitis externa. The company is headquartered in Irvine, California.